m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

Robert D. Hilgers, Sewa S. Legha, George A. Johnston, David S. Alberts, Ronald L. Stephens, Bill L. Tranum, Edward V. Hannigan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalInvestigational New Drugs
Issue number3
StatePublished - Sep 1984


  • 4′-(9-acridinyl-amino)methanesulfon-m-anisidide
  • Phase II clinical trial
  • adenocarcinoma of the endometrium
  • m-AMSA

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'm-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study'. Together they form a unique fingerprint.

Cite this